Table 1.
Characteristics of deceased SARS-CoV-2 positive MS patients. BMI: body-mass-index; COPD: chronic obstructive pulmonary disease; DMT: disease modifying therapy; EDSS: Expanded Disability Status Scale; f: female; m: male; N/A: not available; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; VTE: venous thromboembolism.
| Pat. ID | Sex (m/f) | Age | Disease Duration (years) | Disease Phase | EDSS | DMT | Comorbidities |
|---|---|---|---|---|---|---|---|
| 01 | N/A | 6th decade | 25 | SPMS | 7.5 | None | None |
| 02 | N/A | 8th decade | 51 | SPMS | 8 | None | Chronic myelomonocytic leukemia |
| 03 | N/A | 6th decade | 28 | SPMS | 8.5 | None | Ischemic heart disease, COPD |
| 04 | N/A | 8th decade | 22 | PPMS | 8.5 | None | None |
| 05 | N/A | 6th decade | 48 | SPMS | 9 | None | Colorectal cancer |
| 06 | N/A | 7th decade | 35 | SPMS | 9 | None | Arterial hypertension |
| 07 | N/A | 4th decade | 28 | SPMS | 9.5 | None | None |
| 08 | N/A | N/A | N/A | N/A | 4 | None | Obesity |
| 09 | N/A | N/A | N/A | N/A | 7 | None | Asthma |
| 10 | f | 50 | 13 | RRMS | N/A | None | Obesity, hypertension, hypothyroidism |
| 11 | f | 65 | 31 | SPMS | N/A | None | Intrathecal baclofen pump |
| 12 | N/A | 5th decade | 23 | RRMS | 1.5 | None | Obesity |
| 13 | N/A | 7th decade | 47 | RRMS | 5 | None | None |
| 14 | m | 74 | N/A | SPMS | 8.5 | None | Coronary artery disease, hypertension, diabetes mellitus, COPD, cardiomyopathy |
| 15 | N/A | 5th decade | 22 | PPMS | 7 | Rituximab | None |
| 16 | N/A | N/A | N/A | N/A | N/A | Rituximab | Sjögren’s syndrome, hypothyroidism |
| 17 | N/A | N/A | N/A | N/A | N/A | Rituximab | Obesity |
| 18 | f | 43 | 18 | SPMS | 6.5 | Rituximab | Hypothyroidism |
| 19 | m | 42 | 18 | RRMS | N/A | Rituximab | Hodgkin lymphoma, anticoagulation for VTE, intrathecal baclofen pump |
| 20 | m | 66 | 33 | SPMS | N/A | Ocrelizumab | History of testicular and prostate cancer, intrathecal baclofen pump |
| 21 | N/A | N/A | N/A | N/A | 6 | Ocrelizumab | COPD |
| 22 | f | 60 | 19 | RRMS | N/A | Natalizumab | Obesity, coronary artery disease, hypertension |
| 23 | f | 51 | 14 | RRMS | 6.5 | Natalizumab | Obesity, hypertension, recurrent urinary tract infections |
| 24 | f | 55 | N/A | SPMS | 7.5 | Teriflunomide | Myotonic dystrophy |
| 25 | N/A | 3th decade | 5 | RRMS | 3 | Teriflunomide | Obesity |
| 26 | N/A | N/A | N/A | N/A | N/A | Fingolimod | Severe cognitive impairment |
| 27 | N/A | 5th decade | 5 | RRMS | 3 | Dimethyl-fumarate | Obesity, grade 2 lymphopenia, schizophrenia |
| 28 | m | 71 | 30 | SPMS | N/A | Glatiramer-acetate | Obesity, anticoagulation for VTE |